Skip to main content
SpringerLink
Log in
Book cover

Clinical PET and PET/CT pp 161–180Cite as

Oncology—Breast and Female Reproductive System

  • Chapter

  • 1369 Accesses

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliography

Breast Cancer

  1. Adler LP, Faulhaber PF, Schnur KC, et al. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET. Radiology 1997; 203:323–7.

    PubMed  CAS  Google Scholar 

  2. Adler LP, Weinberg IN, Bradbury MS, et al. Method for combined FDG-PET and radiographic imaging of primary breast cancers. Breast J 2003; 9:163–6.

    Article  PubMed  Google Scholar 

  3. Ahmad A, Barrington S, Maisey M, et al. Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients. Br J Cancer 1999; 478–82.

    Google Scholar 

  4. Avril N, Dose J, Janicke F, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 1996; 88:1204–9.

    PubMed  CAS  Google Scholar 

  5. Avril N, Menzel M, Dose J, et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001; 42:9–16.

    PubMed  CAS  Google Scholar 

  6. Avril N, Rose CA, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000; 18:3495–502.

    PubMed  CAS  Google Scholar 

  7. Barranger E, Grahek D, Antoine M, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer. Ann Surg Oncol 2003; 10:622–7.

    Article  PubMed  Google Scholar 

  8. Bassa P, Kim EE, Inoue T, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-deoxyglucose in breast cancer. J Nucl Med 1996; 37:931–8.

    PubMed  CAS  Google Scholar 

  9. Bender H, Kirst J, Palmedo H, et al. Value of 18-fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 1997; 17:1687–92.

    PubMed  CAS  Google Scholar 

  10. Bombardieri E, Crippa F. PET imaging in breast cancer. Q J Nucl Med 2001; 45:245–56.

    PubMed  CAS  Google Scholar 

  11. Brix G, Henze M, Knopp MV, et al. Comparison of pharmacokinetic MRI and [18F]fluorodeoxyglucose PET in the diagnosis of breast cancer: initial experience. Eur Radiol 2001; 11:2058–70.

    Article  PubMed  CAS  Google Scholar 

  12. Brown RS, Goodman TM, Zasadny KR, et al. Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol 2002; 29:443–53.

    PubMed  CAS  Google Scholar 

  13. Buck A, Schirrmeister H, Kuhn T, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002; 29:1317–23.

    Article  PubMed  CAS  Google Scholar 

  14. Burcombe RJ, Makris A, Pittam M, et al. Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography. Eur J Cancer 2002; 38:375–9.

    Article  PubMed  CAS  Google Scholar 

  15. Crippa F, Agresti R, Seregni E, et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 1998; 39:4–8.

    PubMed  CAS  Google Scholar 

  16. Crowe JP Jr, Adler LP, Shenk RR, et al. Positron emission tomography and breast masses: comparison with clinical, mammographic and pathological findings. Ann Surg Oncol 1994; 1:132–40.

    PubMed  Google Scholar 

  17. Dose J, Bleckmann C, Bachmann S, et al. Comparison of fluorodeoxyglucose positron emission tomography and “conventional diagnostic procedures” for the detection of distant metastases in breast cancer patients. Nul Med Commun 2002; 23:857–64.

    CAS  Google Scholar 

  18. Eubank WB, Mankoff DA, Vesselle HJ, et al. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics 2002; 22:5–17.

    PubMed  Google Scholar 

  19. Flanagan FL, Dehdashti F, Siegel BA. PET in breast cancer. Semin Nucl Med 1998; 28:290–302.

    PubMed  CAS  Google Scholar 

  20. Gennari A, Donati S, Salvadori B, et al. Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer 2000; 1:156–61.

    Article  PubMed  CAS  Google Scholar 

  21. Goerres GW, Miche SC, Fehr MK, et al. Follow-up of women with breast cancer: comparison between MRI and FDG PET. Eur Radiol 2003; 13:1633–44.

    Article  Google Scholar 

  22. Greco M, Crippa M, Agresti R, et al. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 2001; 93:630–5.

    Article  PubMed  CAS  Google Scholar 

  23. Hoh CK, Schipers C. 18-FDG imaging in breast cancer. Semin Nucl Med 1999; 29:49–56.

    PubMed  CAS  Google Scholar 

  24. Hubner KF, Smith GT, Thie JA, et al. The potential of F-18-FDG PET in breast cancer. Detection of primary lesions, axillary lymph node metastases, or distant metastases. Clin Positron Imaging 2000; 3:197–205.

    PubMed  Google Scholar 

  25. Jadvar H, Epstein A, Conti PS. Evaluation of suspected recurrent and metastatic breast carcinoma with 18F-FDG PET. J Nucl Med 2003; 44(5 Suppl):170P.

    Google Scholar 

  26. Kamel EM, Wyss MT, Fehr MK, et al. [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol 2003; 129:147–53.

    PubMed  Google Scholar 

  27. Minn H, Soini I. [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow-up of treatment in advanced breast cancer. Eur J Nucl Med 1989; 15:61–6.

    Article  PubMed  CAS  Google Scholar 

  28. Moon DH, Maddahi J, Silverman DH, et al. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998; 39:431–5.

    PubMed  CAS  Google Scholar 

  29. Nair N, Ali A, Dowlatshahi K, et al. Positron emission tomography with fluorine-18 fluorodeoxyglucose to evaluate response of early breast carcinoma treated with stereotactic interstitial laser therapy. Clin Nucl Med 2000; 25:505–7.

    Article  PubMed  CAS  Google Scholar 

  30. Nieweg OE, Kim EE, Wong WH, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71:3920–5.

    PubMed  CAS  Google Scholar 

  31. Oshida M, Uno K, Suzuki M, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer 1998; 82:2227–34.

    Article  PubMed  CAS  Google Scholar 

  32. Raylman RR, Majewski S, Weisenberger AG, et al. Positron emission mammography-guided breast biopsy. J Nucl Med 2001; 42:960–6.

    PubMed  CAS  Google Scholar 

  33. Rose C, Dose J, Avril N. Positron emission tomography for the diagnosis of breast cancer. Nucl Med Commun 2002; 23:613–8.

    Article  PubMed  CAS  Google Scholar 

  34. Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000; 18:1689–95.

    PubMed  CAS  Google Scholar 

  35. Scirrmeister H, Kuhn T, Guhlmann A, et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001; 28:351–8.

    Google Scholar 

  36. Siggelkow W, Zimmy M, Faridi A, et al. The value of positron emission tomography in the follow-up for breast cancer. Anticancer Res 2003; 23:1859–67.

    PubMed  Google Scholar 

  37. Smith IC, Ogston KN, Whitford P, et al. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Ann Surg 1998; 228:220–7.

    Article  PubMed  CAS  Google Scholar 

  38. Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000; 18:1676–88.

    PubMed  CAS  Google Scholar 

  39. Suarez M, Perez-Castejon MJ, Jimenez A, et al. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 2002; 46:113–21.

    PubMed  CAS  Google Scholar 

  40. Tse NY, Hoh CK, Hawkins RA, et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992; 216:27–34.

    PubMed  CAS  Google Scholar 

  41. van der Hoeven JJ, Hoekstra OS, Comans EF, et al. Determinants of diagnostic performance of [F18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 2002; 236:619–24.

    PubMed  Google Scholar 

  42. Vranjesevic D, Filmont JE, Meta J, et al. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med 2002; 43:325–9.

    PubMed  Google Scholar 

  43. Vranjesevic D, Schiepers C, Silverman DH, et al. Relationship between 18F-FDG uptake and breast density in women with normal breast tissue. J Nucl Med 2003; 44:1238–42.

    PubMed  Google Scholar 

  44. Wahl RL, Cody RL, Hutchins GD, et al. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analog 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179:765–70.

    PubMed  CAS  Google Scholar 

  45. Wahl RL, Helvie MA, Chang AE, et al. Detection of breast cancer in women after augmentation mammoplasty using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 1994; 35:872–5.

    PubMed  CAS  Google Scholar 

  46. Wahl RL, Siegel BA, Coleman RE, et al. Prospective multi-center study of axillary nodal staging with FDG positron emission tomography in breast cancer. J Nucl Med 2003; 44(5 Suppl):77P.

    Google Scholar 

  47. Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11:2101–11.

    PubMed  CAS  Google Scholar 

  48. Wahl RL. Current status of PET in breast cancer imaging, staging, and therapy. Semin Roentgenol 2001; 36:250–60.

    PubMed  CAS  Google Scholar 

  49. Wu D, Gambhir SS. Positron emission tomography in diagnosis and management of invasive breast cancer: current status and future perspectives. Clin Breast Cancer 2003; 4(Suppl 1):S55–63.

    PubMed  Google Scholar 

  50. Yap CS, Seltzer MA, Schiepers C, et al. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician’s perspective. J Nucl Med 2001; 42:1334–7.

    PubMed  CAS  Google Scholar 

Ovarian Cancer

  1. Blodgett TM, Meltzer CC, Townsend DW, et al. PET/CT in re-staging patients with ovarian carcinoma. J Nucl Med 2002; 5(suppl):310P.

    Google Scholar 

  2. Bristow RE, del Carmen MG, Pannu HK, et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003; 90:519–28.

    Article  PubMed  Google Scholar 

  3. Bristow RE, Simpkins F, Pannu HK, et al. Positron emission tomography for detecting clinically occult surgically respectable metastatic ovarian cancer. Gynecol Oncol 2002; 85:196–200.

    Article  PubMed  Google Scholar 

  4. Casey MJ, Gupta NC, Muths CK: Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol 1994; 53:331–8.

    Article  PubMed  CAS  Google Scholar 

  5. Chang WC, Hung YC, Kao CH, et al. Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker. Neoplasm 2002; 49:329–33.

    CAS  Google Scholar 

  6. Cho SM, Ha HK, Byaun JY, et al. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. AJR 2002; 179:391–5.

    PubMed  Google Scholar 

  7. Cohade C, Mourtziks KA, Pannu HK, et al. Direct comparison of PET and PET/CT in the detection of recurrent ovarian cancer. J Nucl Med 2003; 5(suppl):129P.

    Google Scholar 

  8. Dadparvar S, Chotipanich C, Guan L, et al. 18FDG-PET imaging in detection of recurrent ovarian carcinoma. J Nucl Med 2003; 5(suppl):131P.

    Google Scholar 

  9. Drieskens O, Stroobants S, Gysen M, et al. Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer. Gynecol Obstet Invest 2003; 55:130–4.

    Article  PubMed  CAS  Google Scholar 

  10. Fenchel S, Grab D, Nuessle K, et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 2002; 223:780–8.

    PubMed  Google Scholar 

  11. Fenchel S, Kotzerke J, Stohr I, et al. Preoperative assessment of asymptomatic adnexal tumors by positron emission tomography and F-18 fluorodeoxyglucose. Nukleramedizin 1999; 38:101–7.

    CAS  Google Scholar 

  12. Garcia Velloso MJ, Boan Garcia JF, Villar Luque LM, et al. F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA-125. Rev Esp Med Nucl 2003; 22:217–23.

    PubMed  CAS  Google Scholar 

  13. Holschneider CH, Manuel M, Williams CM, et al. FDG-PET in ovarian cancer: use of the standardized uptake value (SUV) to differentiate physiological bowel cavity from intraperitoneal metastatic tumor. J Nucl Med 2002; 5(suppl):29P.

    Google Scholar 

  14. Hubner KF, McDonald TW, Niethammer JG, et al. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG). Gynecol Oncol 1993; 51:197–204.

    Article  PubMed  CAS  Google Scholar 

  15. Hubner KF, McDonald TW, Smith GT, Thie JA. Detection of recurrent ovarian cancer by PET using FDG. Clin Positron Imaging 1999; 2:346.

    PubMed  Google Scholar 

  16. Ishiko O, Honda K, Hirai K, et al. Diagnosis of metastasis of ovarian clear cell carcinoma to the peritoneum of the abdominal wall by positron emission tomography with (fluorine-18)-2-deoxyglucose. Oncol Rep 2001; 8:67–9.

    PubMed  CAS  Google Scholar 

  17. Israel O, Keidar Z, Bar-Shalom R, et al. Hybrid PET/CT imaging with FDG in management of patients with gynecologic malignancies. J Nucl Med 2003; 5(suppl):129P.

    Google Scholar 

  18. Jadvar H, Tatlidil R, Conti PS: FDG-PET in the evaluation of recurrent ovarian cancer. J Nucl Med 2001; 42(5 Suppl): 286P.

    Google Scholar 

  19. Karlan BY, Hawkins R, Hoh C, et al. Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993; 51:175–81.

    Article  PubMed  CAS  Google Scholar 

  20. Kubik-Huch RA, Dorffler W, von Schulthess GK, et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000; 10:761–7.

    Article  PubMed  CAS  Google Scholar 

  21. Kurokawa T, Yoshida Y, Kawahara K, et al. Whole-body PET with FDG is useful for following up an ovarian cancer patient with only rising CA-125 levels within the normal range. Ann Nucl Med 2002; 16:491–3.

    Article  PubMed  Google Scholar 

  22. Lerman H, Metser U, Grisaru D, et al. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre-and postmenopausal patients: assessment by PET/CT. J Nucl Med 2004; 45:266–71.

    PubMed  Google Scholar 

  23. Mahy N, Mathieu I, Willemart B, et al. The place of PET-FDG in the diagnosis of recurrent ovarian cancer. J Nucl Med 2003; 5(suppl):130P.

    Google Scholar 

  24. Makhija S, Howden N, Edwards R, et al. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol 2002; 85:53–8.

    Article  PubMed  CAS  Google Scholar 

  25. Manuel M, Holschneider CH, Williams CM, et al. Correlation of FDG-PET scans with surgicopathologic findings in ovarian cancers. J Nucl Med 2002; 5(suppl):29P.

    Google Scholar 

  26. Nakamoto Y, Saga T, Ishimori T, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR 176:1449–54.

    Google Scholar 

  27. Pannu HK, Bristow RE, Cohade C, et al. PET-CT in recurrent ovarian cancer: initial observations. Radiographics 2004; 24:209–23.

    PubMed  Google Scholar 

  28. Picchio M, Sironi S, Messa C, et al. Advanced ovarian carcinoma: usefulness of ([(180F]FDG-PET in combination with CT for lesion detection after primary treatment. Q J Nucl Med 2000; 47:77–84.

    Google Scholar 

  29. Rieber A, Nussie K, Stohr I, et al. Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. AJR 2001; 177:123–9.

    PubMed  CAS  Google Scholar 

  30. Rose PG, Faulhaber P, Miraldi F, et al. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol 2001; 82:17–21.

    PubMed  CAS  Google Scholar 

  31. Ryu S, Kim J, Kim Bg, et al. FDG-PET scan cannot substitute for second look operation in patients with ovarian cancer showing clinical complete response with chemotherapy. J Nucl Med 2001; 5(suppl): 286P.

    Google Scholar 

  32. Safaei A, Meta J, Gambhir SS, et al. Impact of whole body PET imaging with FDG on staging and managing patients with ovarian cancer: the referring physician’s point of view. J Nucl Med 2001; 5(suppl):285P.

    Google Scholar 

  33. Schroder W, Zimmy M, Rudlowski C, et al. The role of 18F-fluoro-deoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer. Int J Gynecol Cancer 1999; 9:117–122.

    Article  PubMed  Google Scholar 

  34. Smith GT, Hubner KF, McDonald T, Thie JA. Avoiding second-look surgery and reducing costs in managing patients with ovarian cancer by applying F-18-FDG PET. Clin Positron Imaging 1998; 1:263.

    PubMed  Google Scholar 

  35. Smith GT, Hubner KF, McDonald T, Thie JA. Cost analysis of FDG PET for managing patients with ovarian cancer. Clin Positron Imaging 1999; 2:63–70.

    PubMed  Google Scholar 

  36. Torizuka T, Nobezawa S, Kanno T, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluoro-18]-fluoro-2-deoxy-D-glucose. Eur J Nucl Med Mol Imaging 2002; 29:797–803.

    Article  PubMed  CAS  Google Scholar 

  37. Yen RF, Sun SS, Shen YY, et al. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection recurrent ovarian cancer. Anticancer Res 2001; 21:3691–4.

    PubMed  CAS  Google Scholar 

  38. Yoshida Y, Kurokawa T, Kawahara K, et al. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. AJR 2004; 182:227–33.

    PubMed  Google Scholar 

  39. Yuan CC, Liu RS, Wang PH, et al. Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma. Initial Report. J Reprod Med 1999; 44:775–8.

    PubMed  CAS  Google Scholar 

  40. Zimmy M, Siggelkow W, Schroder W, et al. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 2001; 83:310–5.

    Google Scholar 

Uterine Cancer

  1. Belhocine T. An appraisal of 18F-FDG PET imaging in post-therapy surveillance of uterine cancers: clinical evidence and a research proposal. Int J Gynecol Cancer 2003; 13:228–33.

    PubMed  CAS  Google Scholar 

  2. Belhocine T, De Barsy C, Hustinx R, et al. Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur J Nucl Med Mol Imaging 2002; 29:1132–9.

    Article  PubMed  CAS  Google Scholar 

  3. Cher S, Lay Ergun E. Positron emission tomographic-computed tomographic imaging of a uterine sarcoma. Clin Nucl Med 2003; 28:443–4.

    Article  PubMed  Google Scholar 

  4. Kao CH. FDG uptake in a huge uterine myoma. Clin Nucl Med 2003; 28:249.

    PubMed  Google Scholar 

  5. Lapela M, Leskinen-Kallio S, Varpula M, et al. Imaging of uterine carcinoma by carbon-11-methionine and PET. J Nucl Med 1994; 35:1618–23.

    PubMed  CAS  Google Scholar 

  6. Lentz SS. Endometrial carcinoma diagnosed by positron emission tomography: a case report. Gynecol Oncol 2002; 86:223–4.

    Article  PubMed  Google Scholar 

  7. Nakahara T, Fujii H, Ide M, et al. F-18 FDG uptake in endometrial cancer. Clin Nucl Med 2001; 26:82–3.

    PubMed  CAS  Google Scholar 

  8. Saga T, Higashi T, Ishimori T, et al. Clinical value of FDG-PET in the follow-up of postoperative patients with endometrial cancer. J Nucl Med 2003; 5(suppl):385P.

    Google Scholar 

  9. Umesaki N, Tanaka T, Miyama M, et al. Positron emission tomography using 2-[(18)F]fluoro-2-deoxy-D-glucose in the diagnosis of uterine leiomyosarcoma: a case report. Clin Imaging 2001; 25:203–5.

    Article  PubMed  CAS  Google Scholar 

  10. Umesaki N, Tanaka T, Miyama M, et al. Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging. Gynecol Oncol 2001; 80:372–7.

    Article  PubMed  CAS  Google Scholar 

Cervical Cancer

  1. Aizer-Dannon A, Bar-Am A, Ron IG, et al. Fused functional-anatomic images of metastatic cancer of cervix obtained by a combined gamma camera and X-ray tube hybrid system with an illustrative case and review of the (18)F-fluorodeoxyglucose literature. Gynecol Oncol 2003; 90:453–7.

    Article  PubMed  Google Scholar 

  2. Belhocine T, Thille A, Fridman V, et al. Contribution of whole-body 18FDG PET imaging in the management of cervical cancer. Gynecol Oncol 2002; 87:90–7.

    Article  PubMed  Google Scholar 

  3. Dose J, Hemminger GE, Bohuslavizki KH: Therapy monitoring using FDG-PET in metastatic cervical cancer. Lancet Oncol 2000; 1:106.

    Article  PubMed  CAS  Google Scholar 

  4. Follen M, Levenback CF, Iyer RB, et al. Imaging in cervical cancer. Cancer 2003; 98:2028–38.

    PubMed  Google Scholar 

  5. Grigsby PW, Siegel BA, Dehdashti F, et al. Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys 2003; 55:907–13.

    Article  PubMed  Google Scholar 

  6. Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 2001; 19:3745–9.

    PubMed  CAS  Google Scholar 

  7. Havrilesky LJ, Wong TZ, Secord AA, et al. The role of PET scanning in the detection of recurrent cervical cancer. Gynecol Oncol 2003; 90:186–90.

    Article  PubMed  Google Scholar 

  8. Jadvar H, Conti PS. FDG PET in the evaluation of women with cervical carcinoma. Radiology 2001; 221(P):386.

    Google Scholar 

  9. Karlan BY, Hoh C, Tse N, et al. Whole-body positron emission tomography with (fluorine-18)-2-deoxyglucose can detect metastatic carcinoma of the fallopian tube. Gynecol Oncol 1993; 49:383–8.

    Article  PubMed  CAS  Google Scholar 

  10. Kerr IG, Manji MF, Powe J, et al. Positron emission tomography for the evaluation of metastases in patients with carcinoma of the cervix: a retrospective review. Gynecol Oncol 2001; 81:477–80.

    Article  PubMed  CAS  Google Scholar 

  11. Kuhnel G, Horn LC, Fischer U, et al. 18F-FDG positron emission tomography in cervical carcinoma: preliminary findings. Zentralbl Gynakol 2001; 123:229–35.

    PubMed  CAS  Google Scholar 

  12. Lin WC, Hung YC, Yeh LS, et al. Usefulness of (18)F-fluorodeoxyglucose positron emission tomography to detect para-aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings. Gynecol Oncol 2003; 89:73–6.

    Article  PubMed  Google Scholar 

  13. Ma SY, See LC, Lai CH, et al. Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med 2003; 44:1775–83.

    PubMed  Google Scholar 

  14. Miller TR, Grisby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys 2002; 53:353–9.

    Article  PubMed  Google Scholar 

  15. Miller TR, Pinkus E, Dehdashti F, et al. Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer. J Nucl Med 2003; 44:192–7.

    PubMed  Google Scholar 

  16. Nakamoto Y, Eisbruch A, Achtyes ED, et al. Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy. Gynecol Oncol 2002; 84:289–95.

    Article  PubMed  Google Scholar 

  17. Narayan K, Hicks RJ, Jobling T, et al. A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer: potential impact on treatment. Int J Gynecol cancer 2001; 11:263–71.

    Article  PubMed  CAS  Google Scholar 

  18. Reinhardt MJ, Ehritt-Braun C, Vogelgesang D, et al. Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET. Radiology 2001; 218:776–82.

    PubMed  CAS  Google Scholar 

  19. Rose PG, Adler LP, Rodriguez M, et al. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 1999; 17:41–5.

    PubMed  CAS  Google Scholar 

  20. Ryu SY, Kim MH, Choi SC, et al. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer. J Nucl Med 2003; 44:347–52.

    PubMed  Google Scholar 

  21. Singh AK, Grigsby PW, Dehdashti F, et al. FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma. Int J Radiat Oncol Biol Phys 2003; 56:489–93.

    Article  PubMed  Google Scholar 

  22. Sugawara Y, Eisbruch A, Kosuda S, et al. Evaluation of FDG PET in patients with cervical cancer. J Nucl Med 1999; 40:1125–31.

    PubMed  CAS  Google Scholar 

  23. Sun SS, Chen TC, Yen RF, et al. Value of whole body 18F-fluoro-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer. Anticancer Res 2001; 21(4B):2957–61.

    PubMed  CAS  Google Scholar 

  24. Tatsumi M, Cohade C, Zellars R, et al. Initial experience in imaging uterine cervical cancer with FDG PET-CT: direct comparison with PET. J Nucl Med 2003; 5(suppl):394P.

    Google Scholar 

  25. Tran BN, Grigsby PW, Dehdashti F, et al. Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. Gynecol Oncol 2003; 90:572–6.

    Article  PubMed  Google Scholar 

  26. Umesaki N, Tanaka T, Miyama M, et al. Early and evaluation of therapy in postoperative recurrent cervical cancers by positron emission tomography. Oncol Rep 2000; 7:53–6.

    PubMed  CAS  Google Scholar 

  27. Umesaki N, Tanaka T, Miyama M, et al. The role of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG-PET) in the diagnosis of recurrence and lymph node metastasis of cervical cancer. Oncol Rep 2000; 7:1261–4.

    PubMed  CAS  Google Scholar 

  28. Yeh LS, Hung YC, Shen YY, et al. Detecting para-aortic lymph nodal metastasis by positron emission tomography of 18F-fluorodeoxyglucose in advanced cervical cancer with negative magnetic resonance imaging findings. Oncol Rep 2002; 9:1289–92.

    PubMed  Google Scholar 

  29. Yen TC, Ng KK, Ma SY, et al. Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer. J Clin Oncol 2003; 21:3651–8.

    Article  PubMed  Google Scholar 

  30. Yen TC, See LC, Lai CH, et al. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med 2004; 45:22–9.

    PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag London Limited

About this chapter

Cite this chapter

(2005). Oncology—Breast and Female Reproductive System. In: Clinical PET and PET/CT. Springer, London. https://doi.org/10.1007/1-84628-100-8_10

Download citation

  • DOI: https://doi.org/10.1007/1-84628-100-8_10

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-838-1

  • Online ISBN: 978-1-84628-100-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation